AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36646315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 40 IU combined with COPE
Number of subjects: 180
Study 36646315 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with COPE
Number of subjects: 180
Study 36646322 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0
Study 36646322 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 36646383 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilver Vena venous stent
Number of subjects: 243
Study 36646399 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorite music
Number of subjects: 70
Study 36646399 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music (Unwind)
Number of subjects: 70
Study 36646399 — intervention group
Group type: COMPARATOR
Intervention: White noise (control condition)
Number of subjects: 70
Study 36646563 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-consent
Number of subjects: 129
Study 36646563 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult permission required
Number of subjects: 129
Study 36646563 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental permission required
Number of subjects: 129
Study 36646605 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte to high-density lipoprotein cholesterol ratio (MHR)
Number of subjects: 2451
Study 36646605 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 (Q4) of MHR
Number of subjects: 2451
Study 36646639 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual breast pump
Number of subjects: 60
Study 36646639 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 60
Study 36646639 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 60
Study 36646708 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF) initiation and duration
Number of subjects: 243
Study 36646708 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding (BF)
Number of subjects: 243
Study 36646800 — intervention group
Group type: EXPERIMENTAL
Intervention: non-invasive test
Number of subjects: 143
Study 36646863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention for 8 months
Number of subjects: 0
Study 36646863 — intervention group
Group type: COMPARATOR
Intervention: Standard healthcare (control)
Number of subjects: 0
Study 36646862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee only
Number of subjects: 4347
Study 36646862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee with direct attending supervision
Number of subjects: 4347
Study 36646862 — intervention group
Group type: COMPARATOR
Intervention: Attending only
Number of subjects: 4347
Study 36646862 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 4347
Study 36646994 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable average grip strength trajectory (n=85)
Number of subjects: 131
Study 36646994 — intervention group
Group type: EXPERIMENTAL
Intervention: High grip strength trajectory (n=27)
Number of subjects: 131
Study 36646994 — intervention group
Group type: EXPERIMENTAL
Intervention: Change scores of weight-normalised grip strength
Number of subjects: 131
Study 36646994 — intervention group
Group type: COMPARATOR
Intervention: Trajectory group membership
Number of subjects: 131
Study 36647007 — intervention group
Group type: EXPERIMENTAL
Intervention: IPMN surveillance (imaging and laboratory tests every 6 to 12 months)
Number of subjects: 232
Study 36647028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting time ≥ 8 hours/day
Number of subjects: 0
Study 36647028 — intervention group
Group type: COMPARATOR
Intervention: Sitting time < 8 hours/day
Number of subjects: 0
Study 36647057 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP device (5 cmH2O)
Number of subjects: 25
Study 36647077 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide treatment for 52 weeks
Number of subjects: 20
Study 36647092 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based incentives
Number of subjects: 900
Study 36647092 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based smart lockers
Number of subjects: 900
Study 36647092 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery
Number of subjects: 900
Study 36647092 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 900
Study 36647114 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 531
Study 36647114 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 531
Study 36647114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study 36647120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed therapy
Number of subjects: 73
Study 36647120 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative physiological incoherence with increased preload dependency
Number of subjects: 73
Study 36647177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor exergames (trained five times a week in addition to conventional rehabilitation)
Number of subjects: 40
Study 36647177 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation treatment only (control group)
Number of subjects: 40
Study 36647213 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-HPV positive women (n=231)
Number of subjects: 950
Study 36647213 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative women (n=573)
Number of subjects: 950
Study 36647213 — intervention group
Group type: EXPERIMENTAL
Intervention: Any HPV positive women at mid-gestation
Number of subjects: 950
Study 36647213 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-HPV positive women at mid-gestation
Number of subjects: 950
Study 36647213 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes for PTD, PPROM, PROM, and chorioamnionitis
Number of subjects: 950
Study 36647478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensartinib (225 mg per day)
Number of subjects: 48
Study 36647557 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthScore intervention (six-month health coaching program with Fitbit and weekly coaching sessions)
Number of subjects: 50
Study 36647557 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthScore intervention
Number of subjects: 50
Study 36647565 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK3486 (0.4 mg kg -1 )
Number of subjects: 129
Study 36647565 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.0 mg kg -1 )
Number of subjects: 129
Study 36647565 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK3486
Number of subjects: 129
Study 36647565 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 129
Study 36647599 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour-treating fields therapy
Number of subjects: 40
Study 36647690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach for estimating treatment effect on recurrent events among subjects who would be alive regardless of treatment.
Number of subjects: 0
Study 36647691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 0
Study 36647745 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum thymidine kinase activity (TKa) measured using DiviTum
Number of subjects: 454
Study 36647745 — intervention group
Group type: EXPERIMENTAL
Intervention: New predefined cut-off for TKa
Number of subjects: 454
Study 36647781 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteasome inhibitor (PI) regimen
Number of subjects: 454
Study 36647781 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory drug (IMiD) regimen
Number of subjects: 454
Study 36647781 — intervention group
Group type: EXPERIMENTAL
Intervention: PI+IMiD-based regimen
Number of subjects: 454
Study 36647781 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen
Number of subjects: 454
Study 36647781 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) during first-line therapy
Number of subjects: 454
Study 36647781 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agent-based regimens
Number of subjects: 454
Study 36647781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained MRD negativity
Number of subjects: 454
Study 36648035 — intervention group
Group type: EXPERIMENTAL
Intervention: Definity microbubbles infusion (2 vials diluted in 50 mL of saline; infusion rate: 4-10 mL/min)
Number of subjects: 56
Study 36648039 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-Oxygen-Level Dependent (BOLD) T2-Mapping
Number of subjects: 0
Study 36648054 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic MINOCA (Ath-MINOCA)
Number of subjects: 190
Study 36648054 — intervention group
Group type: COMPARATOR
Intervention: Nonatherosclerotic MINOCA (non-Ath-MINOCA)
Number of subjects: 190
Study 36648054 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic cause
Number of subjects: 190
Study 36648132 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication-defective herpes simplex virus (HSV) 2 vaccine
Number of subjects: 0
Study 36648215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (various strategies including immunotherapies, chemotherapy, targeted treatments)
Number of subjects: 402
Study 36648215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (various strategies)
Number of subjects: 402
Study 36648215 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant targeted treatment with dabrafenib and trametinib
Number of subjects: 402
Study 36648215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy with talimogene laherparepvec
Number of subjects: 402
Study 36648215 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant immunotherapy (combined ipilimumab and nivolumab)
Number of subjects: 402
Study 36648215 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant combination treatment
Number of subjects: 402
Study 36648215 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant HDI plus chemotherapy
Number of subjects: 402
Study 36648249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Number of subjects: 0
Study 36648259 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased miR-145 expression at T2
Number of subjects: 124
Study 36648259 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased miR-145 expression greater than 0.222 at T2
Number of subjects: 124
Study 36648259 — intervention group
Group type: COMPARATOR
Intervention: No miRNAs
Number of subjects: 124
Study 36648260 — intervention group
Group type: EXPERIMENTAL
Intervention: ARN-FI group
Number of subjects: 76
Study 36648467 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (n=1431)
Number of subjects: 2859
Study 36648467 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (n=1428)
Number of subjects: 2859
Study 36648467 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (n=536)
Number of subjects: 2859
Study 36648467 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (n=577)
Number of subjects: 2859
Study 36648542 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal ischemic index (EMII) positivity on postoperative day 1 (POD 1)
Number of subjects: 58
Study 36648553 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass
Number of subjects: 32
Study 36648553 — intervention group
Group type: COMPARATOR
Intervention: Surgical groups (Roux-en-Y gastric bypass, sleeve gastrectomy)
Number of subjects: 32
Study 36648553 — intervention group
Group type: COMPARATOR
Intervention: Post-bariatric hypoglycaemia
Number of subjects: 32
Study 36648553 — intervention group
Group type: COMPARATOR
Intervention: Other hormonal responses
Number of subjects: 32
Study 36648594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg Q4W
Number of subjects: 108
Study 36648594 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (45/90 mg weight-based at baseline and week 4, then every 12 weeks)
Number of subjects: 108
Study 36648594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Q4W through week 16, then bimekizumab 320 mg Q4W)
Number of subjects: 108
Study 36648627 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg twice daily for 5 days
Number of subjects: 55
Study 36648627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 36648627 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 55
Study 36648744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IND/LNG-IUS 8 (15.4 mg IND)
Number of subjects: 174
Study 36648744 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-dose IND/LNG-IUS 8 (12.5 mg IND)
Number of subjects: 174
Study 36648744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IND/LNG-IUS 8 (6.5 mg IND)
Number of subjects: 174
Study 36648744 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS 8 (control group, 13.5 mg LNG)
Number of subjects: 174
Study 36648744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- and middle-dose IND/LNG-IUS 8
Number of subjects: 174
Study 36648926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) of the medial geniculate body (MGB)
Number of subjects: 6
Study 36648999 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated convolutional neural network (CNN) approach using Dixon-based MRI
Number of subjects: 136
Study 36649008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigulixostat 50 mg
Number of subjects: 143
Study 36649008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigulixostat 100 mg
Number of subjects: 143
Study 36649008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigulixostat 200 mg
Number of subjects: 143
Study 36649008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 36649008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigulixostat (all doses)
Number of subjects: 143
Study 36649068 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Enabled Collaborative Care (TECC) model for diabetes management and mental health support
Number of subjects: 30
Study 36649072 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 1
Study 36649086 — intervention group
Group type: EXPERIMENTAL
Intervention: Early expansion of CD36- nonclassical monocytes on day 1 (D1)
Number of subjects: 15
Study 36649086 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer cells on day 3 (D3)
Number of subjects: 15
Study 36649086 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular T helper cells from day 1 to day 3 (D1-D3)
Number of subjects: 15
Study 36649086 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cells on day 3 (D3)
Number of subjects: 15
Study 36649086 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cell expansion on day 3 (D3)
Number of subjects: 15
Study 36649086 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma cell maturation on days 11-14 (D11-D14)
Number of subjects: 15
Study 36649152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal alcohol biosensors (TAC)
Number of subjects: 0
Study 36649152 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers (PEth)
Number of subjects: 0
Study 36649152 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report (TLFB)
Number of subjects: 0
Study 36649157 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 66
Study 36649157 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MBCT
Number of subjects: 66
Study 36649192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection after preoperative chemoradiotherapy (n = 139)
Number of subjects: 409
Study 36649192 — intervention group
Group type: COMPARATOR
Intervention: Lateral pelvic lymph node dissection without preoperative chemoradiotherapy (n = 270)
Number of subjects: 409
Study 36649192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection after preoperative chemoradiotherapy
Number of subjects: 409
Study 36649248 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nitrites (tertile 3 vs. 1)
Number of subjects: 104168
Study 36649248 — intervention group
Group type: EXPERIMENTAL
Intervention: Foods and water-originated nitrites (tertile 3 vs. 1)
Number of subjects: 104168
Study 36649248 — intervention group
Group type: EXPERIMENTAL
Intervention: Additives-originated nitrites (higher consumers vs. non-consumers)
Number of subjects: 104168
Study 36649248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (e250, higher consumers vs. non-consumers)
Number of subjects: 104168
Study 36649248 — intervention group
Group type: COMPARATOR
Intervention: Total, foods and water-originated, or additives-originated nitrates
Number of subjects: 104168
Study 36649339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin titration regimen (initial-incremental rate of 6 milliunits/min)
Number of subjects: 955
Study 36649339 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose titration regimen (initial-incremental rate of 2 milliunits/min)
Number of subjects: 955
Study 36649339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin dose rates exceeding 20 milliunits/min
Number of subjects: 955
Study 36649339 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin dose rates at 20 milliunits/min or less
Number of subjects: 955
Study 36649389 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer ultrathin-strut sirolimus-eluting Orsiro stent (O-SES)
Number of subjects: 2521
Study 36649389 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable polymer biolimus-eluting Nobori stent (N-BES)
Number of subjects: 2521
Study 36649389 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES
Number of subjects: 2521
Study 36649389 — intervention group
Group type: COMPARATOR
Intervention: N-BES
Number of subjects: 2521
Study 36649389 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (within the first year)
Number of subjects: 2521
Study 36649389 — intervention group
Group type: COMPARATOR
Intervention: N-BES (within the first year)
Number of subjects: 2521
Study 36649389 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (from 1 to 5 years)
Number of subjects: 2521
Study 36649389 — intervention group
Group type: COMPARATOR
Intervention: N-BES (from 1 to 5 years)
Number of subjects: 2521
Study 36649484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 36649484 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36649570 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years
Number of subjects: 283
Study 36649570 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 283
Study 36649686 — intervention group
Group type: EXPERIMENTAL
Intervention: Online ERP therapy
Number of subjects: 224
Study 36649686 — intervention group
Group type: COMPARATOR
Intervention: Online psychoeducation
Number of subjects: 224
Study 36649694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 1329
Study 36649694 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 1329
Study 36649713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography-tandem mass spectrometry assay for 3,3'-Cl 2 BPA-G and 3,3'-Cl 2 BPA-S quantification in plasma samples.
Number of subjects: 0
Study 36649753 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight-Plus Programme (CWP)
Number of subjects: 35
Study 36649753 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 35
Study 36649998 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy with No. 14v lymph node dissection
Number of subjects: 0
Study 36649998 — intervention group
Group type: COMPARATOR
Intervention: D2 lymphadenectomy without No. 14v lymph node dissection
Number of subjects: 0
Study 36650011 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV screening
Number of subjects: 903
Study 36650011 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 903
Study 36650020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Number of subjects: 0
Study 36650254 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Behavioural Activation (BA) with therapist support
Number of subjects: 17
Study 36650254 — intervention group
Group type: COMPARATOR
Intervention: Online Behavioural Activation (BA) without therapist support
Number of subjects: 17
Study 36650328 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measurement
Number of subjects: 510
Study 36650328 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic BP measurement
Number of subjects: 510
Study 36650328 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk BP measurement
Number of subjects: 510
Study 36650328 — intervention group
Group type: COMPARATOR
Intervention: ABPM (24-h ambulatory BP monitoring)
Number of subjects: 510
Study 36650329 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 120
Study 36650329 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 120
Study 36650357 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based Y90 radioembolization (low/scout activity of 555 MBq)
Number of subjects: 30
Study 36650405 — intervention group
Group type: EXPERIMENTAL
Intervention: LARS score questionnaire
Number of subjects: 222
Study 36650435 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 58
Study 36650435 — intervention group
Group type: COMPARATOR
Intervention: Deep extubation (ETT Group)
Number of subjects: 58
Study 36650458 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused metacognitive intervention (MCG)
Number of subjects: 43
Study 36650458 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 43
Study 36650502 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused therapy (TFT) + treatment as usual (TAU)
Number of subjects: 158
Study 36650502 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 158